PR Newswire BiotechOriginal article
Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds
Data ReadoutpositivetBEPositive
AI Analysis
Summary
Cell Stem Cell published results showing tBE-mediated base editing therapy achieved durable clinical remission and transfusion independence in sickle cell disease and β-thalassemia patients across Chinese, African, and South/Southeast Asian populations. The therapy demonstrated consistent safety and efficacy across different genetic backgrounds.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
tBE-mediated base editing therapy achieved durable clinical remission in sickle cell disease and β-thalassemia patients across different genetic backgrounds, confirming 100% transfusion independence and safety/efficacy across African SCD patients and South/Southeast Asian TDT patients
Importance:7/10
Sentiment:
0.85
gene therapybase editingsickle cell diseasebeta-thalassemiaclinical remissiontransfusion independenceAsiaAfrica
Read the original article
Published by PR Newswire Biotech on September 8, 2026 12:00 AM